AbbVie combines advanced science, expertise and passion to solve serious health issues and have a remarkable impact on people’s lives. Read through our press releases to see our latest efforts to improve patient care.

If you are a member of the news media and have questions or need additional information, please contact our Communications Team.

Mar 21, 2018

AbbVie and the International Myeloma Foundation Announce Partnership to Study the Role of a Genetic Mutation in Outcomes of Patients with Multiple Myeloma

NORTH CHICAGO, Ill. and NORTH HOLLYWOOD, Calif., March 21, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research and development-based global biopharmaceutical company, and the International Myeloma Foundation (IMF) today announced they have entered into a collaboration to conduct a landmark retrospective chart review study to better understand and help manage multiple myeloma (MM), the second most common blood cancer.1

Mar 13, 2018

AbbVie Announces Positive Topline Results from Second Phase 3 Study Evaluating Investigational Elagolix in Women with Uterine Fibroids

NORTH CHICAGO, Ill., March 13, 2018 /PRNewswire/ -- AbbVie (NYSE:ABBV), a global research and development-based biopharmaceutical company, in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX), announced that the Phase 3 ELARIS UF-II study (M12-817) of elagolix met its primary endpoint. Results from the second of two pivotal Phase 3 studies demonstrated at month six that elagolix (300 mg twice daily), in combination with low-dose hormone (add-back) therapy (estradiol 1.0 mg / norethindrone acetate 0.5 mg), reduced heavy menstrual bleeding with 76.2 percent (p<0.001) of women with uterine fibroids achieving clinical response compared to placebo (10.1 percent), as measured by the alkaline hematin method. Clinical response was defined as menstrual blood loss volume of less than 80 mL during month six and a 50 percent or greater reduction in menstrual blood loss volume from baseline to month six. The study also met all ranked secondary endpoints (p<0.02) at month six.1

Mar 05, 2018

Julianne Hough Encourages Women to "Speak Up for Endo" during Endometriosis Awareness Month

NORTH CHICAGO, Ill., March 5, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research and development based global biopharmaceutical company, announced that actress, dancer and Emmy Award-winning choreographer Julianne Hough is encouraging women to discuss symptoms of endometriosis and advocate for their own care through a campaign called "SpeakENDO."  The campaign, sponsored by AbbVie, is for women who want to learn more about endometriosis, those trying to find out what may be causing their symptoms and women already diagnosed with endometriosis.

Mar 02, 2018

Biogen and AbbVie Announce the Voluntary Worldwide Withdrawal of Marketing Authorizations for ZINBRYTA® (daclizumab) for Relapsing Multiple Sclerosis

CAMBRIDGE, Mass. & NORTH CHICAGO, Ill.--(BUSINESS WIRE)--Biogen (Nasdaq:BIIB) and AbbVie (NYSE:ABBV) today announced the voluntary worldwide withdrawal of ZINBRYTA for relapsing multiple sclerosis. The companies believe that characterizing the complex and evolving benefit/risk profile of ZINBRYTA will not be possible going forward given the limited number of patients being treated.
Feb 26, 2018

AbbVie to Present at the Barclays Global Healthcare Conference

NORTH CHICAGO, Ill., Feb. 26, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Barclays Global Healthcare Conference on Thursday, March 15, 2018. Bill Chase, executive vice president and chief financial officer, will present at 8 a.m. Central time.

Feb 22, 2018

AbbVie to Present at the Cowen and Company 38th Annual Health Care Conference

Appearance cancelled due to weather in Boston
NORTH CHICAGO, Ill., Feb. 22, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Cowen and Company 38th Annual Health Care Conference on Wednesday, March 14, 2018. Bill Chase, executive vice president and chief financial officer will present at 7:00 a.m. Central time.

Feb 21, 2018

AbbVie Announces Positive Topline Results from Phase 3 Study Evaluating Investigational Elagolix in Women with Uterine Fibroids

NORTH CHICAGO, Ill., Feb. 21, 2018 /PRNewswire/ -- AbbVie (NYSE:ABBV), a global research and development-based biopharmaceutical company, in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX), announced that the Phase 3 ELARIS UF-I study (M12-815) of elagolix met its primary endpoint. Results from the first of two pivotal Phase 3 studies demonstrated at month six that elagolix, in combination with low-dose hormone (add-back) therapy, reduced heavy menstrual bleeding with 68.5 percent (p<0.001) of women with uterine fibroids achieving clinical response compared to placebo (8.7 percent), as measured by the alkaline hematin method. Clinical response was defined as menstrual blood loss volume of less than 80 mL during month six and a 50 percent or greater reduction in menstrual blood loss volume from baseline to month six. The study also met all ranked secondary endpoints (p<0.001) at month six.4

Feb 20, 2018

AbbVie and Voyager Therapeutics Announce Global Strategic Collaboration to Develop Potential New Treatments for Alzheimer's Disease and Other Tau-Related Neurodegenerative Diseases

NORTH CHICAGO, Ill. and CAMBRIDGE, Mass., Feb. 20, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, and Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company, today announced that they have entered into an exclusive strategic collaboration and option agreement to develop and commercialize vectorized antibodies directed against tau for the treatment of Alzheimer's disease and other neurodegenerative diseases. This collaboration combines AbbVie's monoclonal antibody expertise, global clinical development and commercial capabilities with Voyager's gene therapy platform and expertise that enables generating adeno-associated viral (AAV) vectors for the treatment of neurodegenerative diseases.

Feb 17, 2018

AbbVie Presents New Positive Late-Breaking Data from Two Phase 3 Psoriasis Trials of Risankizumab at the 2018 American Academy of Dermatology Annual Meeting

NORTH CHICAGO, Ill., Feb. 17, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global research and development-based biopharmaceutical company, today presented new positive results from the pivotal Phase 3 ultIMMa-1 and ultIMMa-2 replicate clinical trials that evaluated the safety and efficacy of risankizumab (150 mg) compared to placebo or ustekinumab (45 or 90 mg, based on patient weight). These results were featured during the "Late-breaking Research: Clinical Trials" session at the 2018 American Academy of Dermatology Annual Meeting in San Diego.

Feb 17, 2018

AbbVie Presents New Late-Breaking Phase 2b Data on Upadacitinib in Atopic Dermatitis at the 2018 American Academy of Dermatology Annual Meeting

NORTH CHICAGO, Ill., Feb. 17, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global research and development-based biopharmaceutical company, today presented new positive results from a Phase 2b dose-ranging study evaluating upadacitinib, an investigational, once-daily oral JAK1-selective inhibitor, in adult patients with moderate to severe atopic dermatitis. These results were featured during the "Late-Breaking Research: Clinical Trials" session at the 2018 American Academy of Dermatology (AAD) Annual Meeting in San Diego. Upadacitinib is not approved by regulatory authorities and its safety and efficacy have not been established.